Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) EPS (Basic): 2010-2025

Historic EPS (Basic) for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to -$0.22.

  • Anika Therapeutics' EPS (Basic) rose 89.16% to -$0.22 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.38, marking a year-over-year increase of 65.05%. This contributed to the annual value of -$3.83 for FY2024, which is 32.09% up from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' EPS (Basic) is -$0.22, which was up 33.33% from -$0.33 recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' EPS (Basic) peaked at $0.45 during Q2 2021, and registered a low of -$4.30 during Q4 2023.
  • Over the past 3 years, Anika Therapeutics' median EPS (Basic) value was -$0.34 (recorded in 2025), while the average stood at -$0.96.
  • Its EPS (Basic) has fluctuated over the past 5 years, first surged by 183.33% in 2021, then crashed by 1,164.71% in 2023.
  • Anika Therapeutics' EPS (Basic) (Quarterly) stood at -$0.40 in 2021, then increased by 15.00% to -$0.34 in 2022, then tumbled by 1,164.71% to -$4.30 in 2023, then surged by 65.35% to -$1.49 in 2024, then surged by 89.16% to -$0.22 in 2025.
  • Its EPS (Basic) was -$0.22 in Q3 2025, compared to -$0.33 in Q2 2025 and -$0.34 in Q1 2025.